Evidence Level
Cetyl Myristoleate (CMO) is a compound that has shown promise in alleviating symptoms of osteoarthritis (OA). A randomized controlled trial by Hesslink et al. (2002) involving 60 patients with knee OA demonstrated that cetylated fatty acids significantly reduced pain and improved range of motion compared to placebo over 68 days. Similarly, Kraemer et al. (2004) conducted a study with 40 participants and found that a topical cream containing cetylated fatty acids enhanced functional mobility and quality of life in knee OA patients more effectively than placebo.
The mechanistic basis for CMO's effects was first identified by Diehl and May (1994), who observed that Swiss albino mice, which naturally produce CMO, are resistant to experimentally induced arthritis. This finding suggests a potential anti-inflammatory or protective role of CMO in joint health. However, while these studies provide encouraging results, larger multi-center trials are needed to confirm the efficacy and safety of CMO across diverse populations.
In addition to CMO, Morelli et al. (2003) reviewed alternative therapies for OA, noting that glucosamine and chondroitin may alleviate symptoms but do not halt disease progression, whereas S-adenosylmethionine shows promise with fewer side effects than nonsteroidal anti-inflammatory drugs (NSAIDs). These findings highlight the need for continued research into complementary approaches for managing OA.